<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494363</url>
  </required_header>
  <id_info>
    <org_study_id>SCH01</org_study_id>
    <nct_id>NCT01494363</nct_id>
  </id_info>
  <brief_title>Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer</brief_title>
  <official_title>Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soon Chun Hyang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Goals

           The primary goal of this phase II trial is to:

           evaluate the response rate of combination chemotherapy with Fluorouracil, Leucovorin,
           Oxaliplatin, and Irinotecan in patients with locally advanced or metastatic Biliary
           tract cancer as first-line chemotherapy

           Secondary goals are to:

           evaluate the treatment-related toxicities of this combination, investigate
           progression-free survival(PFS) and overall survival(OS) in this population

        2. Design The proposed clinical trial is an open label, non-comparative, multicenter phase
           II trial according to the two stage testing design by Simon two-stage testing procedure
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of response will be assessed according to RECIST v1.1 criteria after completion of every two cycles. Evaluation will be conducted by physical examination, X-ray, or CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of toxicity will be assessed according to NCI CTCAE version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who were diagnosed as adenocarcinoma of gallbladder or biliary tract
             histologically or cytologically

          2. Unresectable locally advanced, metastatic, or recurrent biliary tract cancer

          3. Patients must be ≥ 18 , ≤ 75 years old of age

          4. ECOG performance status ≤ 2

          5. At least one lesion that can be measured by imaging (CT/MRI) according to the Response
             Evaluation Criteria in Solid Tumors (RECIST v1.1)

          6. Estimated life expectancy of more than 3 months

          7. Adequate bone marrow function (absolute neutrophil count [ANC] ≥ 1,500/µL, hemoglobin
             ≥ 9.0 g/dL [correction by transfusion is acceptable], and platelets ≥ 100,000/µL)

          8. Adequate kidney function (serum creatinine &lt; 1.5 x upper limit of normal [ULN])

          9. Adequate liver function (serum total bilirubin &lt; 3.0xULN; serum transaminases levels &lt;
             5.0xUNL)

         10. Provision of fully informed consent prior to any study specific procedures

        Exclusion Criteria:

          1. Other tumor type than adenocarcinoma

          2. Any previous history of chemotherapy for biliary tract cancer (prior
             neoadjuvant/adjuvant chemotherapy is allowed, if recurrence occurred more than 6
             months after completion of previous chemotherapy)

          3. Patients with second primary cancer (except, adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
             curatively treated with no evidence of disease for ≥5 years)

          4. Patients who received radiotherapy on target lesion within 6 months prior to study
             treatment

          5. Patients with defect of central nervous system (CNS) or any psychiatric disorders and
             CNS metastases

          6. Patients who received major surgery within 4 weeks of starting study treatment or was
             not recovered from any effects of major surgery

          7. Pregnant or breastfeeding women and women of childbearing potential not employing
             adequate contraception

          8. Other serious illness or medical conditions A. Clinically significant cardiac disease
             (uncontrolled congestive heart disease despite treatment [NYHA class III or IV],
             symptomatic coronary artery disease, unstable angina or myocardial infarction,
             conduction abnormality like grade 2 AV block, serious arrhythmia needed for
             medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver
             cirrhosis (≥ Child-Pugh class B) C. History of significant neurologic or psychiatric
             disorders including dementia or seizures D. Active uncontrolled infection E. Other
             serious underlying medical conditions which could impair the ability of the patient to
             participate in the study

          9. Concomitant administration of any other experimental drug under investigation, or
             concomitant chemotherapy, hormonal therapy, or immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hyun Jung Kim</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Jung Kim, M.D.</last_name>
      <phone>+82-32-621-5114</phone>
      <email>khjbless@schmc.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Han Jo Kim</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Jo Kim, M.D.</last_name>
      <phone>+82-41-570-3693</phone>
      <email>hzmd@schmc.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nam Su Lee</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nam Su Lee, M.D.</last_name>
      <phone>+82-2-709-9114</phone>
      <email>mdnslee@schmc.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <last_update_submitted>December 14, 2011</last_update_submitted>
  <last_update_submitted_qc>December 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soon Chun Hyang University</investigator_affiliation>
    <investigator_full_name>Nam Su Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

